Evidence map›Paper›PMID 42282703›Full record

ArticlebioRxiv : the preprint server for biology2026

Aberrant chromatin remodeling influences human neural cell fate change in Trisomy 21.

Jenny A Klein, Suraj Upadhya, Anna Nathanson, Dana Silvian, Eric F Zaniewski, Robert Morris, Wilhelm Haas, Lindy E Barrett

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jenny A KleinStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge MA 02142, USA.
Suraj UpadhyaStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge MA 02142, USA.
Anna NathansonStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge MA 02142, USA.
Dana SilvianStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge MA 02142, USA.
Eric F ZaniewskiKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, US, and Department of Medicine, Harvard Medical School, Boston, MA, USA.
Robert MorrisKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, US, and Department of Medicine, Harvard Medical School, Boston, MA, USA.
Wilhelm HaasKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, US, and Department of Medicine, Harvard Medical School, Boston, MA, USA.
Lindy E BarrettStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge MA 02142, USA.

Funding

Investigating epigenetic mechanisms in Down syndrome using human cellular modelsR01HD111876 · NICHD · BROAD INSTITUTE, INC. · PI Ralda Nehme · 2023 to 2026
$2.7M
NICHD NIH HHS R01 HD111876
6 · The paper itself

Abstract

Correct neural progenitor cell (NPC) fate specification is essential to produce the full complement of neurons and glia needed for proper brain structure and function. Neurodevelopmental disorders, including the autosomal aneuploidy Down syndrome (DS), or Trisomy 21 (T21), are frequently associated with impaired cell fate decisions which ultimately drive differences in overall brain size and cell type composition through unknown mechanisms. To uncover mechanisms driving altered NPC fate in T21, we leverage paired single-nuclei transcriptomic and epigenomic analyses of human induced pluripotent stem cell (iPSC)-derived NPCs and their differentiated progeny coupled with in depth clonal cell fate, cell cycle, and proteomic analyses. Here we show that T21 NPCs fail to activate an orchestrated neurogenic program during the earliest stages of fate specification, instead maintaining a repressive chromatin structure over neurogenic loci, leading to reduced neurogenesis and continued NPC proliferation. We identify novel enrichment of the repressive histone mark H3K27me3 at fate instructive genes dysregulated across diverse cell and tissue types in T21, with corresponding genome-wide changes in H3K27me3 binding in T21 NPCs. Moreover, pharmacological treatment with an inhibitor of the Polycomb repressive complex 2 (PRC2) which catalyzes H3K27 methylation, is sufficient to partially restore neurogenesis in T21 cells. Collectively, our analyses reveal a chromatin mechanism influencing neurogenic defects in T21.

Indexed as

Down syndromegene regulatory networkH3K27me3humanneural progenitor cellneurogenesisPRC2trisomy 21

Identifiers

PMID42282703
PMCPMC13252092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.